PhaseRx, Inc. (PZRXQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PhaseRx, Inc. (PZRXQ) trades at $0.0001. PhaseRx, Inc. is a biopharmaceutical company developing treatments for inherited liver enzyme deficiencies using its Hybrid mRNA technology. Its pipeline targets urea cycle disorders, aiming for intracellular enzyme replacement. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for PZRXQ: PZRXQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PZRXQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PZRXQ: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →PhaseRx, Inc. (PZRXQ) Healthcare & Pipeline Overview
PhaseRx, Inc. is a biopharmaceutical company specializing in developing treatments for inherited liver enzyme deficiencies. Utilizing its proprietary Hybrid mRNA technology platform, the company focuses on intracellular enzyme replacement for urea cycle disorders, including PRX-OTC, PRX-ASL, and PRX-ASS1, positioning itself in the innovative mRNA therapeutics space.
What Is the Investment Thesis for PZRXQ?
PhaseRx, Inc. presents a research-stage investment profile centered on its innovative Hybrid mRNA technology platform, designed for intracellular enzyme replacement in inherited liver enzyme deficiencies. The company's preclinical pipeline, targeting critical urea cycle disorders such as ornithine transcarbamylase deficiency (PRX-OTC), argininosuccinate lyase deficiency (PRX-ASL), and argininosuccinate synthetase deficiency (PRX-ASS1), addresses areas of significant unmet medical need. The potential value driver lies in the unique mechanism of action of its mRNA platform, which aims to enable the body to produce therapeutic enzymes endogenously, potentially offering a more sustained and effective treatment compared to traditional enzyme replacement therapies. Growth catalysts would involve successful advancement of its pipeline candidates through preclinical studies and into clinical trials, demonstrating safety and efficacy. However, as a preclinical biopharmaceutical entity with a market capitalization of $0.00B and trading on the OTC Other tier, the company faces substantial risks. These include the inherent high failure rates and extensive capital requirements of drug development, the significant timeframes involved in bringing a drug to market, and the heightened volatility and limited liquidity associated with OTC Other-listed securities. The beta of -2.55 suggests a complex relationship with market movements, potentially indicating high sensitivity or specific idiosyncratic factors.
Based on FMP financials and quantitative analysis
PZRXQ Key Highlights
Market Capitalization: $0.00B, reflecting its current valuation as a preclinical-stage biopharmaceutical company.
- Beta: -2.55, indicating a complex or inverse relationship with overall market movements, often seen in highly speculative or distressed assets.
- Employee Count: 10 employees, suggesting a lean operational structure focused on specialized research and development.
- Core Focus: Development of mRNA therapeutics for inherited liver enzyme deficiencies, particularly urea cycle disorders.
- OTC Listing: Trades on the OTC Other tier, signifying a higher risk profile due to minimal disclosure and potential for limited liquidity.
Who Are PZRXQ's Competitors?
PZRXQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PZRXQ's Key Strengths?
Innovative Hybrid mRNA technology platform for intracellular enzyme replacement.
- Focused preclinical pipeline targeting severe inherited liver enzyme deficiencies (urea cycle disorders).
- Addresses significant unmet medical needs in rare genetic diseases.
- Potential for a differentiated therapeutic approach compared to existing treatments.
What Are PZRXQ's Weaknesses?
All pipeline candidates are in the preclinical stage, with no products on the market.
- Limited operational scale with only 10 employees.
- Trades on the OTC Other tier, implying potential for limited liquidity and heightened volatility.
- Unknown disclosure status, which may limit investor access to comprehensive financial information.
What Could Drive PZRXQ Stock Higher?
Advancement of preclinical programs (PRX-OTC, PRX-ASL, PRX-ASS1) through key research milestones.
- Further development and validation of the proprietary Hybrid mRNA technology platform.
- Efforts to secure additional funding or strategic partnerships to support R&D initiatives.
- Any public announcements regarding preclinical data or regulatory interactions.
What Are the Key Risks for PZRXQ?
Financial-distress signal — its Altman Z-Score of -25.01 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High inherent risk of preclinical drug development, including potential for efficacy and safety challenges.
- Significant capital requirements and funding challenges for a preclinical biopharmaceutical company.
- Regulatory hurdles and the lengthy, uncertain path to potential drug approval.
- Intense competition within the mRNA therapeutics and rare disease treatment sectors.
- Risks associated with the OTC Other listing, including limited liquidity, heightened volatility, and unknown disclosure status.
What Are the Growth Opportunities for PZRXQ?
- **Advancement of PRX-OTC for Ornithine Transcarbamylase Deficiency:** PhaseRx's lead program, PRX-OTC, targets ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder. Successful progression of PRX-OTC through preclinical development and into human clinical trials represents a significant growth opportunity. The market for rare disease therapies, particularly those addressing life-threatening conditions like OTC deficiency, often commands premium pricing due to the high unmet medical need and limited treatment options. Demonstrating efficacy and safety in early-stage trials could validate the Hybrid mRNA platform and attract substantial investor interest or strategic partnerships, potentially accelerating its path to market.
- **Development of PRX-ASL for Argininosuccinate Lyase Deficiency:** The program targeting argininosuccinate lyase (ASL) deficiency, PRX-ASL, offers another distinct growth pathway. ASL deficiency is another severe urea cycle disorder requiring lifelong management. Advancing this candidate through preclinical studies and towards Investigational New Drug (IND) application submission would be a critical milestone. The ability of the Hybrid mRNA platform to address multiple distinct enzyme deficiencies within the same therapeutic class underscores its versatility and potential for pipeline expansion. Each successful program validation enhances the overall value proposition of the underlying technology, broadening the company's potential market reach.
- **Progress with PRX-ASS1 for Argininosuccinate Synthetase Deficiency:** PhaseRx's third pipeline candidate, PRX-ASS1, focuses on argininosuccinate synthetase (ASS1) deficiency, also known as Citrullinemia Type I. The successful development of PRX-ASS1 would further solidify the company's expertise in urea cycle disorders and demonstrate the broad applicability of its Hybrid mRNA technology. Each distinct program addresses a specific patient population with a severe genetic condition, contributing to a diversified portfolio of potential therapies. Positive preclinical data for PRX-ASS1 could attract further funding or collaborative opportunities, supporting the company's long-term development strategy in rare genetic diseases.
- **Expansion of Hybrid mRNA Platform to Other Inherited Enzyme Deficiencies:** Beyond urea cycle disorders, the Hybrid mRNA technology platform possesses the inherent potential to be applied to a wider range of inherited enzyme deficiencies affecting the liver and potentially other organs. Identifying and initiating new preclinical programs for additional rare genetic diseases represents a significant long-term growth opportunity. This expansion could unlock new market segments, diversify the company's risk profile, and leverage its core technological expertise across a broader therapeutic landscape. Successful proof-of-concept in initial programs would de-risk future applications of the platform.
- **Potential for Strategic Partnerships or Licensing Agreements:** Given PhaseRx's preclinical stage and specialized technology, securing strategic partnerships with larger pharmaceutical companies or entering into licensing agreements for its Hybrid mRNA platform or specific pipeline assets could be a crucial growth driver. Such collaborations could provide non-dilutive funding, access to advanced development and commercialization expertise, and broader market reach. A successful partnership could validate the technology's commercial potential and accelerate the development timeline for its therapeutic candidates, providing resources beyond its current operational capacity.
What Are PZRXQ's Competitive Advantages?
- Proprietary Hybrid mRNA technology platform, designed for intracellular enzyme replacement.
- Specialized focus and expertise in developing therapeutics for inherited liver enzyme deficiencies.
- Targeted preclinical pipeline addressing specific, high-unmet-need urea cycle disorders.
- Potential for a unique mechanism of action that enables endogenous enzyme production.
What Does PZRXQ Do?
PhaseRx, Inc., established in 2006 and headquartered in Seattle, Washington, operates as a biopharmaceutical company dedicated to addressing inherited enzyme deficiencies that primarily impact liver function. The company's core therapeutic approach revolves around intracellular enzyme replacement, a strategy powered by its distinctive Hybrid mRNA technology platform. This innovative platform is designed to enable the body's own cells to produce the absent or deficient enzymes directly, thereby aiming to correct the underlying metabolic imbalance. PhaseRx's pipeline is specifically concentrated on several programs targeting urea cycle disorders, a group of rare genetic conditions that can lead to the accumulation of ammonia in the blood, causing severe neurological damage if left untreated. Key programs in its preclinical pipeline include PRX-OTC, which is being developed for ornithine transcarbamylase deficiency; PRX-ASL, aimed at treating argininosuccinate lyase deficiency; and PRX-ASS1, focused on argininosuccinate synthetase deficiency. These programs represent the company's commitment to developing novel mRNA therapeutics for diseases with significant unmet medical needs. As a preclinical-stage company, PhaseRx is engaged in the foundational research and development necessary to advance these therapeutic candidates through the rigorous stages of drug discovery and development. Its focus on a specialized technology and specific rare diseases positions it within the niche but high-potential market of genetic disease therapies, aiming to provide transformative treatments where current options may be limited or insufficient. The company maintains a lean operational structure with 10 employees, emphasizing specialized expertise in its biopharmaceutical endeavors.
What Products and Services Does PZRXQ Offer?
- Develops biopharmaceutical treatments for inherited enzyme deficiencies.
- Focuses on conditions primarily affecting the liver.
- Utilizes a proprietary Hybrid mRNA technology platform.
- Aims to achieve intracellular enzyme replacement directly within the body's cells.
- Pipeline includes programs specifically targeting urea cycle disorders.
- Developing PRX-OTC for ornithine transcarbamylase deficiency.
- Developing PRX-ASL for argininosuccinate lyase deficiency.
- Developing PRX-ASS1 for argininosuccinate synthetase deficiency.
How Does PZRXQ Make Money?
- Primarily engaged in research and development of novel mRNA therapeutic candidates.
- Seeks to advance preclinical pipeline assets through various stages of drug discovery.
- Potential future revenue generation through the commercialization of approved drugs.
- May pursue licensing agreements or strategic partnerships for its technology or pipeline assets.
- Relies on capital raises and investor funding to finance its ongoing preclinical development.
What Industry Does PZRXQ Operate In?
PhaseRx, Inc. operates within the highly specialized and capital-intensive biotechnology industry, specifically focusing on mRNA therapeutics for rare genetic diseases. This sector is characterized by rapid scientific advancements, particularly in gene therapy and nucleic acid-based medicines, which hold immense promise for conditions previously considered untreatable. The broader biotechnology market is driven by an increasing understanding of disease mechanisms, technological innovation in drug delivery, and a growing demand for precision medicine. PhaseRx's niche in inherited liver enzyme deficiencies, particularly urea cycle disorders, places it in a segment with high unmet medical need but also significant research and development challenges. The competitive landscape includes established pharmaceutical companies and numerous biotech startups exploring various gene editing, gene therapy, and mRNA platforms. Success in this industry is heavily reliant on intellectual property, clinical trial outcomes, and regulatory approvals. PhaseRx's positioning with its Hybrid mRNA technology aims to differentiate its approach to intracellular enzyme replacement within this competitive and evolving therapeutic space.
Who Are PZRXQ's Key Customers?
- Future patients suffering from inherited liver enzyme deficiencies, particularly urea cycle disorders.
- Healthcare providers, including specialists in genetic metabolic diseases and hepatology.
- Hospitals and specialized treatment centers that manage rare genetic conditions.
Financial Health
PhaseRx, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.01 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for PhaseRx, Inc. stands at 101.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 7.99 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
PhaseRx, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Robert W. Overell. PZRXQ has traded publicly since 2016.
PZRXQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- There's been a noticeable uptick in mentions about potential restructuring or acquisition, fueling speculation that someone sees hidden value in PhaseRx's assets despite the bankruptcy.
- The community seems to be latching onto the 'phoenix from the ashes' narrative, hoping for a miraculous turnaround or reverse merger scenario.
- Some are pointing to the company's remaining intellectual property as a potential goldmine if acquired by a larger player in the gene therapy space.
- Despite the bankruptcy, there's a contingent that believes the underlying science still holds promise and could be revived under new management or ownership.
Bear Case
- The company is bankrupt; that's a fundamental red flag that can't be ignored, regardless of any perceived potential. Think Lehman Brothers.
- Community sentiment, while hopeful in some corners, is largely resigned to the reality of the situation; the overall mood is pessimistic.
- Insider activity is likely minimal or non-existent at this stage, suggesting those with the most knowledge have moved on.
- Market perception is overwhelmingly negative; PhaseRx is viewed as a cautionary tale, making any significant recovery highly improbable.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PZRXQ Latest News
No recent news available for PZRXQ.
PZRXQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PZRXQ.
Price Targets
Wall Street price target analysis for PZRXQ.
PZRXQ MoonshotScore
What does this score mean?
The MoonshotScore rates PZRXQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Robert W. Overell
Chief Executive Officer
Unknown. Information regarding Robert W. Overell's specific career history, educational background, and previous leadership roles beyond his current position at PhaseRx, Inc. is not provided in the available source data. His tenure as CEO is associated with managing a team of 10 employees at the Seattle-based biopharmaceutical company.
Track Record: Unknown. Specific achievements, strategic decisions, or company milestones directly attributable to Robert W. Overell's leadership at PhaseRx, Inc. are not detailed in the provided information. The company's focus on developing its Hybrid mRNA technology and preclinical pipeline for urea cycle disorders represents its ongoing strategic direction.
PZRXQ OTC Market Information
PhaseRx, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial health, governance, and minimum share prices, OTC Other companies face minimal to no reporting standards. This tier typically includes companies that are distressed, defunct, or have not provided current information to OTC Markets Group. It signifies a higher risk profile compared to OTCQX or OTCQB, which have more robust disclosure requirements.
- OTC Tier: OTC Other
- Limited liquidity and heightened volatility due to OTC Other listing.
- Unknown disclosure status, impeding access to critical financial and operational information.
- Potential for delisting or further market tier degradation if compliance issues arise.
- Increased susceptibility to fraud and manipulation due to less regulatory oversight.
- Challenges in capital raising given the speculative nature of the OTC Other market.
- Verify any available regulatory filings or company announcements for financial updates.
- Assess the current status of its preclinical pipeline and R&D activities.
- Investigate any potential restructuring plans or corporate actions.
- Research the management team's history and track record, if information becomes available.
- Understand the specific risks associated with investing in preclinical biopharmaceutical companies.
- Monitor trading volumes and bid-ask spreads to gauge liquidity.
- Seek independent verification of any claims made by the company.
- Established in 2006, indicating a history as an operating entity.
- Specific therapeutic focus on inherited liver enzyme deficiencies and urea cycle disorders.
- Named CEO, Robert W. Overell, suggesting a formal leadership structure.
- Proprietary Hybrid mRNA technology platform, indicating a foundation in scientific innovation.
PhaseRx, Inc. Healthcare Stock: Key Questions Answered
What is PhaseRx, Inc.'s core technology and how does it work?
PhaseRx, Inc. is centered on its proprietary Hybrid mRNA technology platform, a sophisticated approach to treating inherited enzyme deficiencies. This technology is designed for intracellular enzyme replacement, meaning it aims to enable the body's own cells to produce the enzymes that are either absent or dysfunctional due to genetic mutations.
What is PhaseRx, Inc.'s drug pipeline status?
PhaseRx, Inc.'s drug pipeline is currently in the preclinical stage, focusing entirely on developing novel mRNA therapeutics for inherited enzyme deficiencies, specifically urea cycle disorders. The company has three primary programs: PRX-OTC, targeting ornithine transcarbamylase deficiency; PRX-ASL, aimed at argininosuccinate lyase deficiency; and PRX-ASS1, for argininosuccinate synthetase deficiency.
What are the primary risks associated with investing in PZRXQ, particularly as an OTC-listed company?
Investing in PZRXQ carries significant risks, primarily due to its preclinical stage and OTC Other listing. As a biopharmaceutical company, it faces the inherent high failure rates, extensive capital requirements, and long development timelines associated with drug discovery. All its pipeline candidates are preclinical, meaning there's no guarantee of future clinical success or market approval.
What are the key factors to evaluate for PZRXQ?
Evaluate PZRXQ on fundamentals, analyst consensus, and risk factors. PhaseRx, Inc. presents a research-stage investment profile centered on its innovative Hybrid mRNA technology platform, designed for intracellular enzyme replacement in inherited liver enzyme deficiencies. Not financial advice.
How frequently does PZRXQ data refresh on this page?
PZRXQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PZRXQ's recent stock price performance?
PhaseRx, Inc. (PZRXQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Hybrid mRNA technology platform for intracellular enzyme replacement. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PZRXQ overvalued or undervalued right now?
PhaseRx, Inc. (PZRXQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PZRXQ before investing?
Before investing in PhaseRx, Inc. (PZRXQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's preclinical stage and OTC Other listing with unknown disclosure status.
- Financial metrics beyond market cap and beta are not available in the provided source data.
- Specific market sizes and timelines for growth opportunities are not provided and thus not included.